PMV Pharmaceuticals, Inc. PMVP · Stock Open PMV Pharmaceuticals, Inc. in new tab
PMV Pharmaceuticals, Inc. Analysis (PMVP)
Is PMV Pharmaceuticals, Inc. a good investment? PMV Pharmaceuticals, Inc. (PMVP) is currently trading at 1.12 USD. Market analysts have a consensus price target of 4.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: PMV Pharmaceuticals, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.09.
Investor FAQ
Does PMV Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is PMV Pharmaceuticals, Inc.?
PMV Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.48.
Company Profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Community Discussion